Share on StockTwits
 

Equities research analysts at UBS AG raised their target price on shares of Insmed Incorporated (NASDAQ:INSM) from $17.50 to $31.00 in a research note issued to investors on Monday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. UBS AG’s target price would suggest a potential upside of 82.03% from the company’s current price.

A number of other firms have also recently commented on INSM. Analysts at Piper Jaffray initiated coverage on shares of Insmed Incorporated in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $34.00 price target on the stock. Separately, analysts at HC Wainwright initiated coverage on shares of Insmed Incorporated in a research note to investors on Monday, November 11th. They set a “buy” rating and a $25.00 price target on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Insmed Incorporated in a research note to investors on Thursday, October 17th. They set a “market perform” rating on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $28.50.

Shares of Insmed Incorporated (NASDAQ:INSM) traded up 3.05% during mid-day trading on Monday, hitting $17.55. 231,753 shares of the company’s stock traded hands. Insmed Incorporated has a 1-year low of $5.56 and a 1-year high of $17.60. The stock’s 50-day moving average is $16.08 and its 200-day moving average is $13.92. The company’s market cap is $686.4 million.

Insmed Incorporated (NASDAQ:INSM) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.41) by $0.05. Analysts expect that Insmed Incorporated will post $-1.65 EPS for the current fiscal year.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company specializing in recombinant protein drug development.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.